SOX17 Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension
Circulation · 23.05.2023 · 147 (21) · 1606-1621
DOI: 10.1161/circulationaha.122.061940 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 23.05.2023. Verfasst von Rachel Walters und 16 weiteren Autor:innen. Beteiligte Einrichtung: National Heart and Lung Institute, Hammersmith Hospital, Imperial College, London, United Kingdom (R.W., E.V., J.A., C.-N.C., Y.W., A.A., O.D., L.Z.,…. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, NIGMS NIH HHS, Medical Research Council.
Abstract (Originalsprache)
Background
Pulmonary arterial hypertension (PAH) is a rare disease characterized by remodeling of the pulmonary arteries, increased vascular resistance, and right-sided heart failure. Genome-wide association studies of idiopathic/heritable PAH established novel genetic risk variants, including conserved enhancers upstream of transcription factor (TF) SOX17 containing 2 independent signals. SOX17 is an important TF in embryonic development and in the homeostasis of pulmonary artery endothelial cells (hPAEC) in the adult. Rare pathogenic mutations in SOX17 cause heritable PAH. We hypothesized that PAH risk alleles in an enhancer region impair TF-binding upstream of SOX17 , which in turn reduces SOX17 expression and contributes to disturbed endothelial cell function and PAH development.
Methods
CRISPR manipulation and siRNA were used to modulate SOX17 expression. Electromobility shift assays were used to confirm in silico – predicted TF differential binding to the SOX17 variants. Functional assays in hPAECs were used to establish the biological consequences of SOX17 loss. In silico analysis with the connectivity map was used to predict compounds that rescue disturbed SOX17 signaling. Mice with deletion of the SOX17 -signal 1 enhancer region ( SOX17 -4593/enhKO) were phenotyped in response to chronic hypoxia and SU5416/hypoxia.
Results
CRISPR inhibition of SOX17 -signal 2 and deletion of SOX17 -signal 1 specifically decreased SOX17 expression. Electromobility shift assays demonstrated differential binding of hPAEC nuclear proteins to the risk and nonrisk alleles from both SOX17 signals. Candidate TFs HOXA5 and ROR-α were identified through in silico analysis and antibody electromobility shift assays. Analysis of the hPAEC transcriptomes revealed alteration of PAH-relevant pathways on SOX17 silencing, including extracellular matrix regulation. SOX17 silencing in hPAECs resulted in increased apoptosis, proliferation, and disturbance of barrier function. With the use of the connectivity map, compounds were identified that reversed the SOX17-dysfunction transcriptomic signatures in hPAECs. SOX17 enhancer knockout in mice reduced lung SOX17 expression, resulting in more severe pulmonary vascular leak and hypoxia or SU5416/hypoxia-induced pulmonary hypertension.
Conclusions
Common PAH risk variants upstream of the SOX17 promoter reduce endothelial SOX17 expression, at least in part, through differential binding of HOXA5 and ROR-α. Reduced SOX17 expression results in disturbed hPAEC function and PAH. Existing drug compounds can reverse the disturbed SOX17 pulmonary endothelial transcriptomic signature.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Heart and Lung Institute, Hammersmith Hospital, Imperial College, London, United Kingdom (R.W., E.V., J.A., C.-N.C., Y.W., A.A., O.D., L.Z., F.S., M.R.W., L.Z., C.J.R.).
- Department of Pulmonary Medicine, Amsterdam University Medical Center, The Netherlands (J.A.).
- Division of Hematology/Oncology, Department of Medicine (O.D.L.), Rhode Island Hospital and Warren Alpert Medical School of Brown University, Providence.
- Section of Genetics & Genomics, Department of Metabolism, Digestion & Reproduction, Hammersmith Hospital, Imperial College, London, United Kingdom (I.C., J.F.).
- Computational Biology and Health Genomics Programme, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Spain (J.F.).
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Barcelona, Spain (J.F.).
ORCID-Profile: Rachel Walters, Jurjan Aman, Olin D Liang, Lin Zhao, Farah Sabrin, Inês Cebola, Nicholas W Morrell, James R Klinger, Martin R Wilkins, Lan Zhao, Christopher J Rhodes
Förderung
- British Heart Foundation
- NIGMS NIH HHS
- Medical Research Council
- Wellcome Trust
- European Research Council
- NHLBI NIH HHS
Zitieren
APA
Walters, R., Vasilaki, E., Aman, J., Chen, C. N., Wu, Y., Liang, O. D., Ashek, A., Dubois, O., Zhao, L., Sabrin, F., Cebola, I., Ferrer, J., Morrell, N. W., Klinger, J. R., Wilkins, M. R., Zhao, L., & Rhodes, C. J. (2023). SOX17 Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension. Circulation, 147(21), 1606-1621. https://doi.org/10.1161/circulationaha.122.061940
Vancouver
Walters R, Vasilaki E, Aman J, Chen CN, Wu Y, Liang OD, et al. SOX17 Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension. Circulation. 2023;147(21):1606-1621. doi:10.1161/circulationaha.122.061940
BibTeX
@article{Walters2023,
author = {Walters, Rachel and Vasilaki, Eleni and Aman, Jurjan and Chen, Chien-Nien and Wu, Yukyee and Liang, Olin D and Ashek, Ali and Dubois, Olivier and Zhao, Lin and Sabrin, Farah and Cebola, Inês and Ferrer, Jorge and Morrell, Nicholas W and Klinger, James R and Wilkins, Martin R and Zhao, Lan and Rhodes, Christopher J},
title = {SOX17 Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension},
journal = {Circulation},
year = {2023},
volume = {147},
number = {21},
pages = {1606--1621},
doi = {10.1161/circulationaha.122.061940}
}
EUVIMED